Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease
Mark Löwenberg(Amsterdam University Medical Centers), Geert D’Haens(Amsterdam University Medical Centers), Peter Bossuyt(Imelda Hospital), Ron A. A. Mathôt(Amsterdam University Medical Centers), Denis Franchimont(McGill University Health Centre), Nahid Mostafavi(Amsterdam University Medical Centers), Frank Hoentjen(Radboud University Nijmegen), Carmen A. Ambarus(Amsterdam University Medical Centers), Pieter Hindryckx(Ghent University Hospital), Theo Rispens(Sanquin), Annick de Vries(Sanquin), C. Janneke van der Woude(Radboud University Nijmegen), Esmé Clasquin(Amsterdam University Medical Centers), Sophie E. Berends(Amsterdam University Medical Centers), Filip Baert(AZ Delta), Séverine Vermeire(KU Leuven)
Cited by 127
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
IgG Subclasses and Allotypes: From Structure to Effector Functions
|Frontiers in Immunology|2014|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k